新京报讯 2月26日,复星医药发布公告,其控股子公司上海复星医药产业发展有限公司(“复星医药产业”)获独家开发和商业化许可的全新机制降磷创新药盐酸替那帕诺片(中国境内商品名:万缇乐)获国家药监局批准上市,用于控制对磷结合剂疗效不充分或不耐受的慢性肾脏病(CKD)成人透析患者的血清磷水平。 长期以来,我国透析患者高磷血症的达标率都低于国际水平,在现有药物治疗下,有相当比例的患者血磷无法达标,资料...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.